Marta BlÃ¡zquez Estrada

List of Publications by Year
in descending order

37 papers	2,467 citations	361413 20 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	3928 citing authors

#	Article	IF	Citations
1	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an InternationalÂCrossover Study With Randomized, Double-Blind Primary Endpoint. Neuromodulation, 2022, 25, 817-828.	0.8	34
2	Constipation Predicts Cognitive Decline in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group. Journal of Parkinson's Disease, 2022, 12, 315-331.	2.8	10
3	Parkinsonâ€™s Disease Motor Subtypes Change with the Progression of the Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Parkinson's Disease, 2022, 12, 935-955.	2.8	3
4	Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease Patients: A 2-Year Follow-Up Study. Diagnostics, 2022, 12, 1147.	2.6	5
5	Falls Predict Acute Hospitalization in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2021, , 1-20.	2.8	5
6	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
7	Identification of sixteen novel candidate genes for late onset Parkinsonâ€™s disease. Molecular Neurodegeneration, 2021, 16, 35.	10.8	41
8	A series of cases with Huntington-like phenotype and intermediate repeats in HTT. Journal of the Neurological Sciences, 2021, 425, 117452.	0.6	3
9	Predictors of Global Non-Motor Symptoms Burden Progression in Parkinsonâ€™s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine, 2021, 11, 626.	2.5	10
10	Present and Future of Parkinsonâ€™s Disease in Spain: PARKINSON-2030 Delphi Project. Brain Sciences, 2021, 11, 1027.	2.3	6
11	Predictors of Loss of Functional Independence in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up and Comparison with a Control Group. Diagnostics, 2021, 11, 1801.	2.6	9
12	Cancer in Parkinsonâ€™s Disease: An Approximation to the Main Risk Factors. Neurodegenerative Diseases, 2021, 21, 36-41.	1.4	1
13	Predictors of clinically significant quality of life impairment in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 118.	5.3	17
14	Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinsonâ€™s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up. Diagnostics, 2021, 11, 2380.	2.6	2
15	Identifying comorbidities and lifestyle factors contributing to the cognitive profile of early Parkinsonâ€™s disease. BMC Neurology, 2021, 21, 477.	1.8	7
16	Nonâ€motor symptom burden is strongly correlated to motor complications in patients with Parkinsonâ€™s disease. European Journal of Neurology, 2020, 27, 1210-1223.	3.3	40
17	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
18	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414

#	Article	IF	Citations
19	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
20	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
21	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	3.1	21
22	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
23	Analysis of the Microâ€RNAâ€133 and PITX3 genes in Parkinson's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1234-1239.	1.7	33
24	5â€²-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	4.4	24
25	Lrrk2 R1441G-related Parkinsonâ€™s disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics, 2009, 10, 347-353.	1.4	41
26	Mutational screening of the mortalin gene (HSPA9) in Parkinsonâ€™s disease. Journal of Neural Transmission, 2009, 116, 1289-1293.	2.8	74
27	Therapeutic extradural cortical stimulation for Parkinson's Disease: Report of six cases and review of the literature. Clinical Neurology and Neurosurgery, 2009, 111, 703-707.	1.4	36
28	Mutational screening of the Mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M) in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 468-470.	2.2	4
29	Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neuroscience Letters, 2008, 432, 79-82.	2.1	30
30	No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. Neuroscience Letters, 2007, 413, 202-205.	2.1	25
31	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Movement Disorders, 2007, 22, 389-392.	3.9	8
32	Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2. Neuroscience Letters, 2006, 410, 80-84.	2.1	52
33	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. Neuroscience Letters, 2005, 380, 257-259.	2.1	7
34	LRRK2 R1441G in Spanish patients with Parkinson's disease. Neuroscience Letters, 2005, 382, 309-311.	2.1	97
35	Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. Journal of the Neurological Sciences, 2005, 236, 49-54.	0.6	97
36	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2004, 370, 151-154.	2.1	65

#	Article	IF	Citations
37	Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neuroscience Letters, 2002, 329, 149-152.	2.1	23